Skip to main content

Table 4 Relationships between the protein expressions and clinicopathological factors in advanced-stage diseases

From: Differential roles of the Wip1–p38–p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas

Stages III–IV (n=41) P53   Phospho-p53   Wip1   Nuclear phospho-p38   Cytoplasmic phospho-p38  
  Positive Negative   High Low   High Low   High Low   High Low  
  n=14 n=27 p-value n=38 n=3 p-value n=5 n=36 p-value n=38 n=3 p-value n=30 n=11 p-value
Age ≥60 6 (43%) 8 (30%) 0.49 13 (34%) 1 (33%) 1 1 (20%) 13 (36%) 0.64 13 (34%) 1 (33%) 1 12 (40%) 2 (18%) 0.28
FIGO stage IV 5 (36%) 8 (30%) 0.73 13 (34%) 0 (0%) 0.54 2 (40%) 11 (31%) 0.64 13 (34%) 0 (0%) 0.54 7 (23%) 6 (55%) 0.073
Pure histology 11 (79%) 24 (89%) 0.39 32 (84%) 3 (100%) 1 5 (100%) 30 (83%) 1 33 (87%) 2 (67%) 0.39 26 (87%) 9 (82%) 0.65
Lymph node metastasis 5 (36%) 15 (56%) 0.33 20 (53%) 0 (0%) 0.23 2 (40%) 18 (50%) 1 20 (53%) 0 (0%) 0.23 16 (53%) 4 (36%) 0.48
Positive peritoneal cytology 12 (86%) 23 (85%) 1 32 (84%) 3 (100%) 1 4 (80%) 31 (86%) 0.57 32 (84%) 3 (100%) 1 26 (87%) 9 (82%) 0.65
Endometriosis present 5 (36%) 11 (41%) 1 15 (39%) 1 (33%) 1 3 (60%) 13 (36%) 0.36 16 (42%) 0 (0%) 0.27 11 (37%) 5 (45%) 0.72
Residual tumor present 5 (36%) 13 (48%) 0.52 15 (39%) 3 (100%) 0.077 2 (40%) 16 (44%) 1 16 (42%) 2 (67%) 0.57 10 (33%) 8 (73%) 0.036
Lymphadenectmy undone 4 (29%) 12 (44%) 0.50 14 (37%) 2 (67%) 0.55 1 (20%) 15 (42%) 0.63 15 (39%) 1 (33%) 1 10 (33%) 6 (55%) 0.29
  1. FIGO International Federation of Gynecology and Obstetrics